CY1108994T1 - Θερμοαναστρεψιμο ανοσοενισχυτικο γαλακτωμα - Google Patents

Θερμοαναστρεψιμο ανοσοενισχυτικο γαλακτωμα

Info

Publication number
CY1108994T1
CY1108994T1 CY20091100455T CY091100455T CY1108994T1 CY 1108994 T1 CY1108994 T1 CY 1108994T1 CY 20091100455 T CY20091100455 T CY 20091100455T CY 091100455 T CY091100455 T CY 091100455T CY 1108994 T1 CY1108994 T1 CY 1108994T1
Authority
CY
Cyprus
Prior art keywords
oil
thermostable
treatment milk
immune treatment
water emulsion
Prior art date
Application number
CY20091100455T
Other languages
English (en)
Inventor
Marie-Françoise Klucker
François Dalencon
Patricia Probeck-Quellec
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0507240A external-priority patent/FR2888117B1/fr
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of CY1108994T1 publication Critical patent/CY1108994T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Η εφεύρεση έχει ως αντικείμενο ένα ενισχυτικό γαλάκτωμα ελαίου σε νερό το οποίο περιέχει τουλάχιστον: σκουαλένιο, ένα υδατικό διαλύτη, ένα μη ιοντικό υδρόφιλο επιφανειοδραστικό το οποίο είναι ένας πολυοξυ-αιθυλενικός αλκυλαιθέρας, ένα μη ιοντικό υδρόφοβο, θερμοανασρέψιμο επιφανειοδραστικό, και του οποίου το 90% του όγκου πληθυσμού των σταγόνων ελαίου έχει μέγεθος κατώτερο των 200 nm. Η εφεύρεση έχει επίσης ως αντικείμενο μια μέθοδο παρασκευής μιας ανοσογόνου σύνθεσης σύμφωνα με την οποία αναμιγνύεται ένα τουλάχιστον αντιγόνο εμβολίου με ένα γαλάκτωμα ελαίου σε νερό, η οποία χαρακτηρίζεται από το ότι λαμβάνεται το γαλάκτωμα ελαίου σε νερό με μια μέθοδο αναστροφής φάσης με μεταβολή της θερμοκρασίας.
CY20091100455T 2005-07-07 2009-04-27 Θερμοαναστρεψιμο ανοσοενισχυτικο γαλακτωμα CY1108994T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0507240A FR2888117B1 (fr) 2005-07-07 2005-07-07 Composition vaccinale comprenant une emulsion thermoreversible
FR0508310 2005-08-04
EP06778810A EP1904099B1 (fr) 2005-07-07 2006-07-07 Emulsion immuno-adjuvante thermoréversible

Publications (1)

Publication Number Publication Date
CY1108994T1 true CY1108994T1 (el) 2014-07-02

Family

ID=37637538

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20091100455T CY1108994T1 (el) 2005-07-07 2009-04-27 Θερμοαναστρεψιμο ανοσοενισχυτικο γαλακτωμα
CY20121100915T CY1113414T1 (el) 2005-07-07 2012-10-03 Θερμοαναστρεψιμο ανοσοενισχυτικο γαλακτωμα

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20121100915T CY1113414T1 (el) 2005-07-07 2012-10-03 Θερμοαναστρεψιμο ανοσοενισχυτικο γαλακτωμα

Country Status (24)

Country Link
EP (2) EP1904099B1 (el)
JP (1) JP5300475B2 (el)
KR (1) KR101328638B1 (el)
CN (1) CN101217977B (el)
AR (1) AR054822A1 (el)
AT (1) ATE424845T1 (el)
AU (1) AU2006268466B2 (el)
BR (1) BRPI0614053A2 (el)
CA (1) CA2613732C (el)
CY (2) CY1108994T1 (el)
DE (1) DE602006005671D1 (el)
DK (2) DK1904099T3 (el)
EA (1) EA012376B1 (el)
ES (2) ES2322102T3 (el)
IL (1) IL187967A0 (el)
MX (1) MX2007016412A (el)
NO (1) NO336369B1 (el)
NZ (1) NZ564173A (el)
PL (2) PL2080522T3 (el)
PT (2) PT1904099E (el)
SG (1) SG163584A1 (el)
SI (2) SI2080522T1 (el)
TN (1) TNSN08001A1 (el)
WO (1) WO2007006939A2 (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061428A1 (es) 2005-03-23 2007-01-16 Glaxosmithkline Biolog Sa Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
AR054822A1 (es) * 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628206A1 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EP1945252B1 (en) 2005-11-04 2013-05-29 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
AU2011213757B2 (en) * 2005-11-04 2013-07-25 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
CA2688589A1 (en) 2007-05-31 2008-12-31 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal hpv peptide vaccination
CN101428145B (zh) * 2007-11-05 2013-01-02 北京生泰尔生物科技有限公司 新型疫苗佐剂
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
BRPI0909820A2 (pt) 2008-03-05 2015-08-11 Sanofi Pasteur Processo para estabilização de composição de vacina contra gripe, para estabilização de composição de vacina contendo adjuvante e para preparação de vacina, composições de vacina, kit de vacina e método de estocagem de uma matéria prima
CA2733356C (en) 2008-08-01 2016-06-07 Gamma Vaccines Pty Limited Influenza vaccines
DK2396032T3 (en) 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenza vaccines with reduced amounts of squalene
AU2010217190B2 (en) 2009-02-25 2012-10-25 Mayne Pharma Llc Topical foam composition
EP2485753A4 (en) 2009-10-09 2013-12-11 Cbio Ltd VARIANTS OF THE CHAPERONINE IN POSITION 10
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
GB201009673D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
BR112013013702A2 (pt) 2010-12-03 2016-09-13 Sanofi Pasteur Ltd composição para imunização contra streptococcus pneumoniae
EP2667891B1 (en) 2011-01-27 2021-10-06 Gamma Vaccines Pty Limited Combination vaccines
EP2578974A1 (en) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Process line for the production of freeze-dried particles
ES2685612T3 (es) 2012-03-23 2018-10-10 Pitney Pharmaceuticals Pty Limited Inhibidores de cinasa para el tratamiento del cáncer
CA2875683A1 (en) 2012-06-05 2013-12-12 The Australian National University Vaccination with interleukin-4 antagonists
WO2013184900A2 (en) 2012-06-06 2013-12-12 Sanofi Pasteur Biologics, Llc Immunogenic compositions and related methods
WO2014016362A1 (en) 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
EP2880014B1 (en) 2012-08-06 2017-05-17 Pitney Pharmaceuticals Pty Limited Compounds for the treatment of mtor pathway related diseases
CN103784953B (zh) * 2012-10-26 2018-04-10 上海医药工业研究院 作为疫苗佐剂的水包油型亚微乳及其制备方法
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
JP6502853B2 (ja) 2012-12-17 2019-04-17 ニューサウス イノベイションズ ピーティーワイ リミテッド ムチンが関与する疾患の処置
CA2934958A1 (en) 2012-12-24 2014-07-03 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
US10364277B2 (en) 2013-07-01 2019-07-30 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
CN105288614A (zh) * 2014-06-18 2016-02-03 潘皓 一种疫苗组合物及其制备方法
WO2016012414A1 (en) 2014-07-21 2016-01-28 Sanofi Pasteur Liquid feeding device for the generation of droplets
CA2980616A1 (en) 2015-03-26 2016-09-29 Gpn Vaccines Pty Ltd Streptococcal vaccine
CN105251002B (zh) * 2015-11-13 2019-02-15 中国人民解放军第三军医大学 一种水包油型纳米乳佐剂及其mrsa纳米乳佐剂疫苗和制备方法
WO2017137085A1 (en) 2016-02-11 2017-08-17 Sanofi Pasteur Meningitidis vaccines comprising subtilinases
US20190105385A1 (en) * 2016-03-23 2019-04-11 Intervet Inc. A combination vaccine against pcv2 virus and mycoplasma hyopneumoniae infection
TWI656882B (zh) * 2016-08-10 2019-04-21 南韓商賽特瑞恩股份有限公司 穩定的液體抗流感病毒抗體醫藥調配物
JP7291398B2 (ja) 2017-03-30 2023-06-15 ザ ユニバーシティー オブ クイーンズランド キメラ分子およびその使用
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
IL300632A (en) 2020-08-24 2023-04-01 Sanofi Pasteur Inc Vaccines against SARS-COV-2 infections

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
WO1989007143A1 (en) 1988-01-29 1989-08-10 Chiron Corporation Recombinant cmv neutralizing proteins
JPH0832638B2 (ja) * 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
US6299848B1 (en) * 1998-09-25 2001-10-09 Hamon Research-Cottrell Process for removing sulfur dioxide out of a gas
BRPI0010612B8 (pt) * 1999-04-19 2021-05-25 Smithkline Beecham Biologicals S A vacinas
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
ATE444735T1 (de) * 2001-03-21 2009-10-15 Madash Llc Thermisch reversible wasser-in-öl-in-wasser- emulsionen
AR054822A1 (es) * 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante

Also Published As

Publication number Publication date
NZ564173A (en) 2010-10-29
ES2390104T3 (es) 2012-11-06
KR101328638B1 (ko) 2013-11-27
DK1904099T3 (da) 2009-06-08
CN101217977B (zh) 2013-03-06
PL1904099T3 (pl) 2009-08-31
ES2322102T3 (es) 2009-06-16
BRPI0614053A2 (pt) 2011-03-09
EP1904099B1 (fr) 2009-03-11
IL187967A0 (en) 2008-03-20
AR054822A1 (es) 2007-07-18
CA2613732C (en) 2013-12-10
EP2080522B1 (fr) 2012-07-04
SI1904099T1 (sl) 2009-08-31
DE602006005671D1 (en) 2009-04-23
TNSN08001A1 (fr) 2009-07-14
NO20080585L (no) 2008-03-26
EA012376B1 (ru) 2009-10-30
CN101217977A (zh) 2008-07-09
JP2009500382A (ja) 2009-01-08
PT2080522E (pt) 2012-10-01
EP1904099A2 (fr) 2008-04-02
EA200800271A1 (ru) 2008-04-28
AU2006268466B2 (en) 2011-11-10
WO2007006939A2 (fr) 2007-01-18
NO336369B1 (no) 2015-08-10
EP2080522A1 (fr) 2009-07-22
SI2080522T1 (sl) 2012-10-30
AU2006268466A1 (en) 2007-01-18
WO2007006939A3 (fr) 2007-04-05
JP5300475B2 (ja) 2013-09-25
ATE424845T1 (de) 2009-03-15
PL2080522T3 (pl) 2012-11-30
KR20080030076A (ko) 2008-04-03
MX2007016412A (es) 2008-03-07
CA2613732A1 (en) 2007-01-18
PT1904099E (pt) 2009-05-29
CY1113414T1 (el) 2016-06-22
SG163584A1 (en) 2010-08-30
DK2080522T3 (da) 2012-10-08

Similar Documents

Publication Publication Date Title
CY1108994T1 (el) Θερμοαναστρεψιμο ανοσοενισχυτικο γαλακτωμα
TW200716165A (en) Novel vaccine formulations
NZ568210A (en) Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
CO6251273A2 (es) Composiciones para vacuna en emulsion que comprenden antigeno y un adyuvante en la fase acuosa y su metodo de elaboracion
EA200900024A1 (ru) Противогриппозная вакцина
EA200901161A1 (ru) Вакцина против гриппа в виде эмульсии типа "масло в воде"
EA200900350A1 (ru) Вакцина, содержащая адъювант в виде эмульсии "масло в воде"
EA200701786A1 (ru) Поливалентная противогриппозная иммуногенная композиция
CL2004000691A1 (es) Emulsion submicrometrica de aceite en agua de utilidad como adyuvante de vacuna que comprende un aceite, un tensoactivo y un componente acuoso y tamano medio de gota inferior a 1 um; procedimiento para preparar la emulsio; composicion de vacuna que c
BRPI0815828A2 (pt) Formulação de emulsão que impede interação através da interface água-óleo
CO4940401A1 (es) Vacunas
ATE513920T1 (de) Herstellung von squalen aus hyperproduzierenden hefen
DE60144240D1 (de) Zusammensetzung mit immunogenen mikroteilchen
BR112022014830A2 (pt) Formulações de vacina para coronavírus
EA201171033A1 (ru) Вакцины против гриппа со сниженным количеством сквалена
CO6300963A2 (es) Una vacuna contra la malaria que comprende p. falciparum y p. vivax
FR2881748B1 (fr) Dispersions silicones aqueuses, formulations notamment de peintures les comprenant et l'un de leurs procedes de preparation
TH72570B (th) อิมัลชันของน้ำมันในน้ำชนิดผ่านการไมโครฟลูอิดไดซ์ และองค์ประกอบของวัคซีน
CY1113746T1 (el) Εμβολιο που περιλαμβανει ανοσοενισχυτικο γαλακτωμα ελαιου σε υδωρ
WO2013148436A3 (en) Cosmetic composition in the form of an oil-in-water emulsion
MX2009010963A (es) Vacuna de influenza de emulsion de aceite en agua.
UA91700C2 (ru) Применение вируса гриппа и адъюванта на основе эмульсии масла-в-воде для индукции cd4 т-клеток и/или улучшенного ответа в-клеток памяти
FR3043558B1 (fr) Composition immunogene sous forme d'emulsion comprenant deux phases dispersees, l'une comprenant un antigene et l'autre comprenant un agent immunostimulant
TH110373B (th) อิมัลชันชนิดน้ำในน้ำมันซึ่งประกอบด้วยอะครีลิกพอลิเมอร์หรือไดเมธิลไดออกทาเดกซิลแอมโมเนียมโบรไมด์ในวัฎภาคที่มีน้ำ
AU2012244663A1 (en) Antigenic formulation